Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with several functions in health and disease ranging from inflammation to cancer. LIF is also a potential target and/or therapeutic agent for diseases such as multiple sclerosis, stroke and even psychological disorders, where the function of LIF as a neurotrophic factor has only recently been explored. In recent years, a limited number of LIF clinical trials have been completed, which partially explains the shortage of effective applications as a therapeutic agent. With the increasing interest from biotechnology companies producing recombinant LIF, this status quo will certainly change, and the potential impact of LIF in terms of disease diagnosis, treatment and management will be realized.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cytogfr.2019.11.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RO8191, a new compound for initiating embryo implantation in mice.
Sci Rep
September 2025
Laboratory of Animal Morphology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Aichi, Japan.
During early pregnancy in mice, leukemia inhibitory factor (LIF) regulates embryo implantation by activating the JAK/STAT3 signaling pathway. The STAT3 pathway has been recognized to play a critical role in embryo implantation; however, it remains unclear whether STAT3 activation alone is sufficient to induce implantation. In this study, we investigated the effects of RO8191, a potential STAT3 activator, on embryo implantation through a series of studies with different mouse models.
View Article and Find Full Text PDFIvermecatin induces cytotoxic effects in SUP-B15 cell line.
Turk J Pediatr
September 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Background: Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required.
View Article and Find Full Text PDFGenetic causality of circulating inflammatory proteins and plasma metabolites in coronary atherosclerosis.
Postgrad Med J
September 2025
Department of Basic Medicine, Shantou University Medical College, 22 Xinling Road, Jinping District, Shantou, Guangdong, 515041, China.
Background: Coronary atherosclerosis is a leading cause of cardiovascular disease and death worldwide. Despite progress in understanding its pathogenesis, the roles of circulating inflammatory proteins and plasma metabolites are complex and not fully elucidated. Existing Mendelian randomization (MR) studies often target isolated biomarkers, lacking comprehensive and mechanistic insights.
View Article and Find Full Text PDFAdvances in the study of TIM3 in myelodysplastic syndrome.
Front Immunol
September 2025
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Myelodysplastic syndromes (MDS) are heterogeneous myeloid clonal disorders derived from hematopoietic stem cells. The incidence of MDS (1.51/100,000 in China, 4-5/100,000 in Europe and America) is higher than any subtype of leukemia.
View Article and Find Full Text PDFEndothelin-Converting Enzyme-Like 1 Regulated by LIF Contributes to Chronic Constriction Injury-Induced Neuropathic Pain in Mice.
CNS Neurosci Ther
September 2025
Department of Anesthesiology, Northern Jiangsu People's Hospital, Yangzhou, China.
Aims: This study is to investigate the role of Endothelin-converting enzyme-like 1 (ECEL1) in neuropathic pain (NP).
Methods: The expression of ECEL1 was modulated by injecting adeno-associated virus 5 (AAV5) carrying Ecel1 shRNA or full-length Ecel1 into the dorsal root ganglion (DRG) of mice with a chronic constriction injury (CCI) model. Then, various nociceptive responses were evaluated.